[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351199-105":59,"doc-detail-351199-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","multi-omic-profiling-defines-three-distinct-molecular-subtypes-of-urothelial-carcinoma-with-implications-for-precision-therapy","Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy","","Urothelial carcinoma (UC) is biologically heterogeneous, yet existing molecular classifications do not fully translate into clinical decision-making. The study develops a molecular classification framework integrating multi-omic evidence, built for transcriptomic and proteomic data from non–muscle-invasive bladder cancer, muscle-invasive bladder cancer, and urothelial cancer cell lines. The framework yields three molecular UC clusters with validated biological and prognostic implications for precision therapy, supporting more actionable stratification.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multi-omic-profiling-defines-three-distinct-molecular-subtypes-of-urothelial-carcinoma-with-implications-for-precision-therapy/351199/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multi-omic-profiling-defines-three-distinct-molecular-subtypes-of-urothelial-carcinoma-with-implications-for-precision-therapy/351199.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical limitation motivates this study on urothelial carcinoma?","Question",{"text":113,"@type":114},"Current molecular classifications for urothelial carcinoma have limited integration into clinical decision-making.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which data types and cancer contexts does the molecular classification framework support?",{"text":118,"@type":114},"It is designed for transcriptomic and proteomic data from non–muscle-invasive bladder cancer, muscle-invasive bladder cancer, and urothelial cancer cell lines.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the main outputs of the multi-omic clustering approach?",{"text":122,"@type":114},"The work defines three urothelial carcinoma molecular clusters validated across transcriptomic and proteomic datasets, with distinct molecular/biological signatures and differing prognostic and therapeutic characteristics.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351199,1790211845,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","DOI: 10.1002/ctm2.70638  \nRESEARCH ARTICLE  \nMulti-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy  \nNils C. H. van Creij1   Piotr Tymoszuk2   Florian Handle3  Andreas Seeber4, 5  Teresa Sellemond1  Agnieszka Martowicz4, 6  Eva Comperat7  Hamed Wafa1   \nSteffen Ormanns8, 9  Michael Günther8, 9   Walther Parson10  Maxim Noeparast11   Frédéric R. Santer1, 12  José Daniel Subiela13  Petros Grivas14  Roger Li15  Zoran Culig1   Renate Pichler1, 16  \n1 Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria  \n2 Data Analytics As a Service Tirol, Wörgl, Austria  \n3XPseq Analytics GmbH, Innsbruck, Austria  \n4 Department of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria  \n5 Department of Oncology, Hematology and Palliative Care, General Hospital of Oberwart, Oberwart, Austria  \n6Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria  \n7 Department of Pathology, Medical University of Vienna, Vienna, Austria  \n8 INNPATH GmbH, Tirol Kliniken Innsbruck, Innsbruck, Austria  \n9 Institute of General Pathology, Medical University of Innsbruck, Innsbruck, Austria  \n10 Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria  \n11Translational Oncology, II. Med Clinics Hematology and Oncology, University of Augsburg, Augsburg, Germany  \n12 Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria  \n13 Department of Urology, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain  \n14 Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, USA  \n15 Department of GU Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA  \n16 Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria  \nClin. Transl. Med. 2026;16:e70638 .  \n[https://doi.org/10.1002/ctm2.70638](https://doi.org/10.1002/ctm2.70638)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nVAN CREIJ et al.  \nCorrespondence  \nRenate Pichler, Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria. [Email:](Email: renate.pichler@i-med.ac.at)[ renate.pichler@i-med.ac.at](Email: renate.pichler@i-med.ac.at)  \nGraphical Abstract  \n∙ We developed three UC clusters, applicable forMIBC and NMIBC, which were validated using transcriptomic-and proteomic datasets.  \n∙ Publically available UC cell lines were assigned to the clusters, to have in vitro models representing each cluster.  \n∙ The clusters differ in molecular and biological signatures, with distinct prognostic and therapeutic characteristics.  \n.  \nDOI: 10.1002/ctm2.70638  \nRESEARCH ARTICLE  \nMulti-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy  \nNils C. H. van Creij1   Piotr Tymoszuk2  Teresa Sellemond1  Agnieszka Martowicz4, 6  \nFlorian Handle3 Eva Comperat7  \nAndreas Seeber4, 5 Hamed Wafa1   \nSteffen Ormanns8, 9  Michael Günther8, 9   Walther Parson10  Maxim Noeparast11   Frédéric R. Santer1, 12  José Daniel Subiela13 Petros Grivas14  Roger Li15  Zoran Culig1   Renate Pichler1, 16  \n1 Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria  \n2 Data Analytics As a Service Tirol, Wörgl, Austria  \n3XPseq Analytics GmbH, Innsbruck, Austria  \n4 Department of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria  \n5 Department of Oncology, Hematology and Palliative Care, General Hospital of Oberwart, Oberwart, Austria  \n6Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria  ","cbCaivhLLy69FgzP","https://ap.wps.com/l/cbCaivhLLy69FgzP","pdf",6209262,36,"English","# Research Article Overview\n## Graphical Abstract Findings\n## Abstract Background and Framework","[{\"question\":\"What clinical limitation motivates this study on urothelial carcinoma?\",\"answer\":\"Current molecular classifications for urothelial carcinoma have limited integration into clinical decision-making.\"},{\"question\":\"Which data types and cancer contexts does the molecular classification framework support?\",\"answer\":\"It is designed for transcriptomic and proteomic data from non–muscle-invasive bladder cancer, muscle-invasive bladder cancer, and urothelial cancer cell lines.\"},{\"question\":\"What are the main outputs of the multi-omic clustering approach?\",\"answer\":\"The work defines three urothelial carcinoma molecular clusters validated across transcriptomic and proteomic datasets, with distinct molecular/biological signatures and differing prognostic and therapeutic characteristics.\"}]","Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy | PDF",1790093038,91,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/290653d950d7e6dd0e3fa3acdab580eb.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34e740c387c619a1fd17da455c779afb.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27a8e8d65727ae09503917ff4a11aa62.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09c9d6eb4de814d4f1ebe6f47dc44997.webp",980,1287]